AbbVie’s Rinvoq (upadacitinib) has been approved by the US Food and Drug Administration (FDA) to treat adults with giant cell ...

The FDA has granted approval for AbbVie’s 15mg Rinvoq (upadacitinib) to treat adults with giant cell arteritis (GCA).

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The S&P 500 edged 0.1% higher on Monday, April 28, eking out a fifth straight winning session to kick off a week of key ...

Shares of AbbVie Inc. rose 3.38% to $192.34 Monday, on what proved to be an all-around great trading session for the stock ...

While AbbVie handily beat expectations this quarter, the company faces declining Humira sales and a challenged aesthetics business, plus the same macro headwinds blowing against the entire industry.

AbbVie has become the latest pharma group to make a big capital investment announcement in the US and court favour with the ...

One of the sources cited by Reuters said that international reference pricing presents an "existential threat to the industry ...

AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV ...

AbbVie took a little shot at the Trump administration’s trade policy, as the drugmaker said Friday that rather than tariffs, ...

Ironwood Pharmaceuticals, Inc.’s IRWD share price has surged by 5.80%, which has investors questioning if this is right time ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...